1718 – PD-L1 (Programmed Death-Ligand 1) immunohistochemistry testing for persistent, recurrent, or metastatic cervical cancer, to determine eligibility for pembrolizumab treatment

Page last updated: 28 August 2023

Application Detail

Description of Medical Service

Immunohistochemistry (IHC) test for evaluation of Programmed Cell Death-Ligand 1 (PD-L1) expression to determine eligibility for treatment with pembrolizumab in patients with persistent, recurrent, or metastatic (spread from where it started) carcinoma of the cervix. The test would be undertaken prior to commencement of pembrolizumab in combination with chemotherapy to enable identification of those patients most likely to benefit from treatment.

Description of Medical Condition

Cervical cancer is the growth of abnormal cells in the lining of the cervix, which if left untreated will slowly spread out of the cervix and into the surrounding tissue and organs.This is a codependent application with PBAC.

Reason for Application

Amendment to MBS item

Medical Service Type

Investigative technology

Previous Application Number/s

Not Applicable

Associated Documentation

Application Form

Application Form (PDF 1274 KB)
Application Form (Word 258 KB)

Consultation Survey

Consultation Survey (PDF 695 KB)
Consultation Survey (Word 72 KB)

MSAC Consultation
MSAC consultation input must be received by no later than Friday, 7 October 2022 for it to be considered by MSAC at its November 2022 meeting.

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation

Not applicable

Assessment Report


Public Summary Document


Meetings for this Application


Expedited - Bypassing PASC


Expedited - Bypassing ESC